<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ETHAMOLIN- ethanolamine oleate injection, solution </strong><br>QOL Medical, LLC.<br></p></div>
<h1>Ethamolin® (Ethanolamine Oleate) Injection, 5%. For Local Intravenous Use Only<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ETHAMOLIN<span class="Sup">®</span> (Ethanolamine Oleate) Injection is a mild sclerosing agent. Chemically it is C<span class="Sub">17</span>H<span class="Sub">33</span>COOH•NH<span class="Sub">2</span>CH<span class="Sub">2</span>CH<span class="Sub">2</span>OH. It has the following structure:</p>
<div class="Figure"><img alt="Ethamolin Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9c1d8c5-443e-400e-a42c-16a25fb47231&amp;name=ethamolin-structure.jpg"></div>
<p></p>
<p>The empirical formula is C<span class="Sub">20</span>H<span class="Sub">41</span>NO<span class="Sub">3</span>, representing a molecular weight of 343.55.</p>
<p>ETHAMOLIN Injection consists of ethanolamine, a basic substance, which when combined with oleic acid, forms a clear <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellow to straw-colored, deliquescent oleate. The pH ranges from 8.0 to 9.0.</p>
<p>ETHAMOLIN Injection is a sterile, apyrogenic, aqueous solution containing in each mL approximately 50 mg of ethanolamine oleate with benzyl alcohol 2% by volume as preservative.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">When injected intravenously, ETHAMOLIN Injection acts primarily by irritation of the intimal endothelium of the vein and produces a sterile dose-related inflammatory response. This results in <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and possible occlusion of the vein. ETHAMOLIN Injection also rapidly diffuses through the venous wall and produces a dose-related extravascular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reaction</span>.</p>
<p>The oleic acid component of ETHAMOLIN Injection is responsible for the inflammatory response, and may also activate coagulation <span class="Italics">in vivo </span>by release of tissue factor and activation of Hageman factor. The ethanolamine component, however, may inhibit fibrin clot formation by chelating calcium, so that a procoagulant action of ETHAMOLIN has not been demonstrated.</p>
<p>After injection, ETHAMOLIN disappears from the injection site within five minutes via the portal vein. When volumes larger than 20 mL are injected, some ETHAMOLIN also flows into the azygos vein through the periesophageal vein. In human autopsy studies it was found that within four days after injection there is neutrophil infiltration of the esophageal wall and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> within six days. Granulation tissue is first seen at ten days, red thrombi obliterating the varices by twenty days, and sclerosis of the varices by two and a half months. The time course of these findings suggests that sclerosis of <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span> will be a delayed rather than an immediate effect of the drug.</p>
<p>The minimum lethal dose of ETHAMOLIN Injection administered intravenously to rabbits is 130 mg/kg.</p>
<p>In dogs, ETHAMOLIN injected into the right atrium at a dose of 1 mL/kg over one minute has been shown to increase extravascular lung water. The maximum recommended human dose is 20 mL, or 0.4 mL/kg for a 50-kg person. The concentration of ETHAMOLIN reaching the lung in human treatment will be less than in the dog studies, but <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusions</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, pulmonary infiltration and <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> have been reported in clinical trials, and minimizing the total per-session dose, especially in patients with concomitant cardiopulmonary disease, is recommended (see <a href="http://pragmaticdata.com/spl/form/#precautions">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ETHAMOLIN Injection is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span> that have recently bled, to prevent rebleeding.</p>
<p>ETHAMOLIN is not indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span> that have not bled. There is no evidence that treatment of this population decreases the likelihood of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Sclerotherapy with ETHAMOLIN has no beneficial effect upon <span class="product-label-link" type="condition" conceptid="192680" conceptname="Portal hypertension">portal hypertension</span>, the cause of <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span>, so that recanalization and collateralization may occur, necessitating reinjection.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ETHAMOLIN Injection should not be administered to subjects with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ethanolamine, oleic acid, or ethanolamine oleate.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">ETHAMOLlN Injection should be used in pregnant women only when clearly needed (see PRECAUTIONS).</p>
<p>The practice of injecting varicosities of the leg with ETHAMOLlN Injection is not supported by adequately-controlled clinical trials. Therefore, such use is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> was reported following injection of a larger than normal volume of ETHAMOLlN Injection into a male who had a known allergic disposition. Although there are only three known reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, the possibility of an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> should be kept in mind, and the physician should be prepared to treat it appropriately. In extreme emergencies, 0.25 mL of a 1:1,000 intravenous solution of epinephrine (0.25 mg) should be used, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> should be controlled with antihistamines.</p>
<p><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> with spontaneous recovery followed injection of 15 to 20 mL of ETHAMOLIN Injection into two women.</p>
<p>The physician should bear in mind that severe injection <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> may result from direct injection of sclerosing agents, especially if excessive volumes are used. At least one fatal case of extensive <span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">esophageal necrosis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported. The drug should be administered by physicians who are familiar with an acceptable injection technique.</p>
<p>Patients in Child Class C are more likely to develop <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span> than those in Classes Aand B. Complications of ulceration, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and delayed <span class="product-label-link" type="condition" conceptid="22955" conceptname="Perforation of esophagus">esophageal perforation</span> appear to occur more frequently when ETHAMOLIN Injection is injected submucosally. This route is not recommended.</p>
<p>In patients with concomitant cardiorespiratory disease, careful monitoring and minimization of the total dose per session is recommended.</p>
<p>Fatal <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span> has occurred in elderly patients undergoing esophageal variceal sclerotherapy with ETHAMOLIN Injection. This adverse event appears to be procedure-related, rather than drug-related; but, as <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of blood and/or stomach contents is not uncommon in patients with <span class="product-label-link" type="condition" conceptid="28779" conceptname="Bleeding esophageal varices">bleeding esophageal varices</span>, special precautions should be taken to prevent its occurrence, especially in elderly and critically-ill subjects.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.1"></a><p></p>
<h2>Pregnancy: (Teratogenic Effects: Pregnancy Category C)</h2>
<p class="First">Animal reproduction studies have not been conducted with ETHAMOLlN Injection. It is also not known whether ETHAMOLIN Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ETHAMOLIN Injection should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.2"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ETHAMOLlN Injection is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.3"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverseReactions"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The reported frequency of complications/adverse events per injection session was 13%. The most common complications were <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>/infiltration (2.1%), <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcer</span> (2.1 %), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (1.8%), retrosterual <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (1.6%), <span class="product-label-link" type="condition" conceptid="4268622" conceptname="Stricture of esophagus">esophageal stricture</span> .(1.3%), and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (1.2%). <br></p>
<p>Other adverse local esophageal reactions have also been reported at rates of 0.1 to 0.4%, including <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, tearing of the esophagus, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> of the mucosa overlying the injected varix, ulceration, stricture, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, periesophageal <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> and perforation (see PRECAUTIONS). These complications appear to be dependent upon the dose and the patient's clinical state.<br></p>
<p><span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span> has been observed in patients following injection of <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span> with ETHAMOLlN. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">retrosternal pain</span> are not infrequently observed during the post-injection period. Fatal <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span> has occurred in patients with <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span> who underwent ETHAMOLIN Injection Sclerotherapy (see PRECAUTIONS). <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> with spontaneous recovery have occurred (see PRECAUTIONS). A case of <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> has been reported. <br></p>
<p>Spinal cord <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> due to occlusion of the anterior spinal artery has been reported in one child eight hours after ETHAMOLIN sclerotherapy.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="L1b078491-41cf-4245-b0d2-13037e5c9f6c"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">There is no potential for drug abuse or <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="overdosage"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage of ETHAMOLIN Injection can result in severe intramural <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of the esophagus. Complications resulting from such overdosage have resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosageAdministration"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Local ETHAMOLIN Injection sclerotherapy of <span class="product-label-link" type="condition" conceptid="24966" conceptname="Esophageal varices">esophageal varices</span> should be performed by physicians who are famillar with an acceptable technique. The usual intravenous dose is 1.5 to 5.0 mL per varix. The maximum dose per treatment session should not exceed 20 mL. Patients with significant liver dysfunction (Child Class C) or concomitant cardiopulmonary disease should usually receive less than the recommended maximum dose. Submucosal injections are not recommended, as they reportedly are more likely to result in ulceration at the site of injection.</p>
<p>To obliterate the varix, injections may be made at the time of theacute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode and then after oIie week, six weeks, three months, and six months, as indicated.</p>
<p>Note: Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="howSupplied"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<a name="tab1"></a><table width="50%">
<caption><span></span></caption>
<tbody class="Headless">
<tr class="First">
<td> NDC</td>
<td> SIZE</td>
</tr>
<tr class="Last">
<td> 67871-4790-6</td>
<td> 2 mL ampule</td>
</tr>
</tbody>
</table>
<p class="First"></p>
<p>ETHAMOLIN® (Ethanolamine Oleate) Injection, 5% is available in 2 mL, sterile, single-use glass ampules supplied as boxes of 10 ampules.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at controlled room temperature, 15°- 30°C (59°- 86°F). Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"></p>
<p><span class="Bold">Distributed by:</span></p>
<p>QOL Medical, LLC</p>
<p>Vero Beach, FL 32963</p>
<p>www.ethamolin.net</p>
<p>phone 1-866-528-4750</p>
<p>fax 1-866-528-4749</p>
<p></p>
<p>213250 / Rev. 08/12</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L65ac0ca3-c0b0-48e7-afc6-c9f6d896fa34"></a><a name="section-13"></a><p></p>
<h1>Carton</h1>
<p class="First"><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9c1d8c5-443e-400e-a42c-16a25fb47231&amp;name=carton.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Lf4938126-d642-4918-bdee-9a9e23b7bcdf"></a><a name="section-14"></a><p></p>
<h1>Label</h1>
<p class="First"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9c1d8c5-443e-400e-a42c-16a25fb47231&amp;name=label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ETHAMOLIN 		
					</strong><br><span class="contentTableReg">ethanolamine oleate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67871-479</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ethanolamine Oleate</strong> (Ethanolamine) </td>
<td class="formItem">Ethanolamine Oleate</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67871-479-06</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019357</td>
<td class="formItem">12/22/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>QOL Medical, LLC.
							(140026258)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c863b995-b91f-4ee3-b9a4-493cf812f722</div>
<div>Set id: a9c1d8c5-443e-400e-a42c-16a25fb47231</div>
<div>Version: 6</div>
<div>Effective Time: 20130423</div>
</div>
</div> <div class="DistributorName">QOL Medical, LLC.</div></p>
</body></html>
